Adjuvant Endocrine Therapy for Breast Cancer During Perimenopause

被引：1
|
作者：
Noss, D. [1 ]
Buchholz, S. [1 ]
Ortmann, O. [1 ]
机构：
[1] Univ Regensburg, Klin Frauenheilkunde & Geburtshilfe, D-93053 Regensburg, Germany
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2010年 / 70卷 / 02期
关键词：
perimenopause; breast cancer; endocrine therapy; menopausal status; PREMENOPAUSAL WOMEN; AROMATASE INHIBITORS; HORMONE; CHEMOTHERAPY; METAANALYSIS; TAMOXIFEN;
D O I：
10.1055/s-0029-1240825
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Adjuvant endocrine treatment plays an important role in the treatment of estrogen responsive breast cancer. The treatment options for premenopausal women differ from those for postmenopausal women. Aromatase inhibitors (AI) improve the outcomes in postmenopausal women, while AI can induce an increase in estrogen secretion and tumor growth in premenopausal women. The standard therapy during premenopause remains tamoxifen with or without ovarian suppression by GnRH analogues. Treatment of perimenopausal breast cancer patients can be more complicated, because it is often difficult to determine menopausal status.
引用
收藏
页码：112 / 116
页数：5
相关论文
共 50 条
  • [1] Adjuvant endocrine therapy for perimenopausal women with early breast cancer
    Ortmann, Olaf
    Cufer, Tanja
    Dixon, J. Michael
    Maass, Nicolai
    Marchetti, Paolo
    Pagani, Olivia
    Pronzato, Paolo
    Semiglazov, Vladimir
    Spano, Jean-Philippe
    Vrdoljak, Eduard
    Wildiers, Hans
    BREAST, 2009, 18 (01) : 2 - 7
  • [2] New options in adjuvant endocrine therapy in breast cancer
    Saltel-Fulero, Aurelien
    Donnadieu, Anne
    Leman-Detours, Solenne
    Cottu, Paul
    BULLETIN DU CANCER, 2016, 103 (01) : 104 - 112
  • [3] Breast cancer adjuvant endocrine therapy
    Cigler, Tessa
    Goss, Paul E.
    CANCER JOURNAL, 2007, 13 (03) : 148 - 155
  • [4] Safety of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer
    Abdulhaq, Haifaa
    Geyer, Charles
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (06): : 595 - 605
  • [5] ENDOCRINE THERAPY IN BREAST CANCER: THE NEOADJUVANT, ADJUVANT, AND METASTATIC APPROACH
    Reinbolt, Raquel E.
    Mangini, Neha
    Hill, Jordan L.
    Levine, Lauren B.
    Dempsey, Jessica L.
    Singaravelu, Janani
    Koehler, Kevin A.
    Talley, Allison
    Lustberg, Maryam B.
    SEMINARS IN ONCOLOGY NURSING, 2015, 31 (02) : 146 - 155
  • [6] Adjuvant endocrine therapy in breast cancer
    Niwinska, Anna
    Litwiniuk, Maria
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2007, 11 (02): : 82 - 88
  • [7] Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients
    Baumgart, J.
    Nilsson, K.
    Evers, A. Stavreus
    Kallak, T. Kunovac
    Kushnir, M. M.
    Bergquist, J.
    Poromaa, I. Sundstrom
    CLIMACTERIC, 2014, 17 (01) : 48 - 54
  • [8] Evolution of endocrine adjuvant therapy for early breast cancer
    Lonning, Per Eystein
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 : S19 - S30
  • [9] Adherence to Adjuvant Endocrine Therapy in Breast Cancer Patients
    Rosso, Roberta
    D'Alonzo, Marta
    Bounous, Valentina Elisabetta
    Actis, Silvia
    Cipullo, Isabella
    Salerno, Elena
    Biglia, Nicoletta
    CURRENT ONCOLOGY, 2023, 30 (02) : 1461 - 1472
  • [10] Initiation of Adjuvant Endocrine Therapy in Black and White Women With Breast Cancer
    Sheppard, Vanessa B.
    de Mendoza, Alejandra Hurtado
    He, Jun
    Jennings, Yvonne
    Edmonds, Megan C.
    Oppong, Bridget A.
    Tadesse, Mahlet G.
    CLINICAL BREAST CANCER, 2018, 18 (05) : 337 - +
12345